GF Fund Management’s Ocular Therapeutix OCUL Stock Holding History

GF Fund Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$38.5K	Buy	5,018 +411	+9%	+$4.02K	﹤0.01%	425
2026 Q2	$45.2K	Sell	4,607 -177	-4%	-$1.6K	﹤0.01%	397
2026 Q1	$40.5K	Buy	4,784 +599	+14%	+$5.71K	﹤0.01%	423
2025 Q4	$50.8K	Buy	4,185 +442	+12%	+$5.37K	﹤0.01%	405
2025 Q3	$43.8K	Sell	3,743 -283	-7%	-$3.38K	﹤0.01%	409
2025 Q2	$37.4K	Hold	4,026	–	–	﹤0.01%	445
2025 Q1	$29.5K	Buy	4,026 +725	+22%	+$5.57K	﹤0.01%	461
2024 Q4	$28.2K	Buy	+3,301	New	+$32.2K	﹤0.01%	438

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Summer Road West Palm Beach, Florida $135M AUM 15.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

GF Fund Management's OCUL Position: Q3 2026 in Review

GF Fund Management increased its Ocular Therapeutix (OCUL) stake by 8.9% in Q3 2026, buying an estimated $4.02K and bringing the position to 5,018 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #425.

GF Fund Management first reported a position in OCUL in Q4 2024 and has held it in 8 quarters since. The position peaked at $50.8K in Q4 2025. 142 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

GF Fund Management held 5,018 shares of Ocular Therapeutix worth $38.5K as of Q3 2026.
GF Fund Management bought 411 Ocular Therapeutix shares in Q3 2026, an estimated $4.02K.
Ocular Therapeutix made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #425 holding.
GF Fund Management first reported a position in Ocular Therapeutix in Q4 2024 and has held it in 8 quarters since.
GF Fund Management's Ocular Therapeutix position peaked at $50.8K in Q4 2025.
142 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.